title: RP105-negative B cells in systemic lupus erythematosus.
abstract: Systemic lupus erythematosus (SLE) is a multisystem disease characterized by B cells producing autoantibodies against nuclear proteins and DNA, especially anti-double-strand DNA (dsDNA) antibodies. RP105 (CD180), the toll-like receptor- (TLR-) associated molecule, is expressed on normal B cells. However, RP105-negative B cells increase in peripheral blood from patients with active SLE. RP105 may regulate B-cell activation, and RP105-negative B cells produce autoantibodies and take part in pathophysiology of SLE. It is possible that targeting RP105-negative B cells is one of the treatments of SLE. In this paper, we discuss the RP105 biology and clinical significance in SLE.
authors.affiliation: Division of Rheumatology, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan. koarada@post.saga-med.ac.jp
authors.forename: Syuichi
authors.initials: S
authors.lastname: Koarada
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Tada
mesh_terms: D000818:Animals; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D015703:Antigens, CD / Q000032:analysis* / Q000502:physiology; D001323:Autoantibodies / Q000096:biosynthesis / Q000276:immunology; D016175:B-Lymphocyte Subsets / Q000276:immunology*; D004195:Disease Models, Animal; D006801:Humans; D016130:Immunophenotyping; D007167:Immunotherapy / Q000379:methods; D008180:Lupus Erythematosus, Systemic / Q000276:immunology*; D008213:Lymphocyte Activation; D051379:Mice; D012216:Rheumatic Diseases / Q000276:immunology; D000069283:Rituximab; D051193:Toll-Like Receptors / Q000276:immunology
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD; D001323:Autoantibodies; C092722:CD180 protein, human; D051193:Toll-Like Receptors; D000069283:Rituximab